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Background: Rabies virus is the causative agent of rabies, a central nervous system disease that is almost invariably
fatal. Currently vaccination is the most effective strategy for preventing rabies, and vaccines are most commonly
produced from cultured cells. Although the vaccine strains employed in China include CTN, aG, PM and PV, there
are no reports of strains that are adapted to primary chick embryo cells for use in human rabies prevention in
China.
Results: Rabies virus strain CTN-1 V was adapted to chick embryo cells by serial passage to obtain the CTNCEC25
strain. A virus growth curve demonstrated that the CTNCEC25 strain achieved high titers in chick embryo cells and
was nonpathogenic to adult mice by intracerebral inoculation. A comparison of the structural protein genes of the
CTNCEC25 strain and the CTN-1 V strain identified eight amino acid changes in the mature M, G and L proteins.
The immunogenicity of the CTNCEC25 strain increased with the adaptation process in chick embryo cells and
conferred high protective efficacy. The inactivated vaccine induced high antibody responses and provided full
protection from an intramuscular challenge in adult mice.
Conclusions: This is the first description of a CTNCEC25 strain that was highly adapted to chick embryo cells, and
both its in vitro and in vivo biological properties were characterized. Given the high immunogenicity and good
propagation characteristics of the CTNCEC25 strain, it has excellent potential to be a candidate for development
into a human rabies vaccine with high safety and quality characteristics for controlling rabies in China.
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Rabies is a widespread neurological disease and is an an-
cient fatal encephalitis with nearly 100% mortality. Ra-
bies reportedly causes approximately 55,000 human
deaths annually throughout the world, the majority of
which occur in Asia [1]. Following India, China has the
second highest number of human cases in the world [2].
The causative agents of rabies are viruses belonging to
the Lyssavirus genus in the family Rhabdoviridae of
which the prototypic rabies virus (RABV) is responsible
for the vast majority of cases. The RABV genome is a
single-stranded, negative-sense RNA of approximately* Correspondence: gcpzxy0402@aliyun.com
Shenzhen Weiguang Biological Products Co., Ltd, Shenzhen 518107,
Guangdong province, China
© 2014 Guo et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.12 kb encoding five structural proteins, and its order (3’
to 5’) is nucleoprotein (N), phosphoprotein (P), matrix
protein (M), glycoprotein (G) and RNA-dependent RNA
polymerase (L) [3]. Between each of the five structural
genes are four non-transcribed intergenic regions of dif-
ferent lengths. In addition, there are two non-coding re-
gions at the end of the genome, namely the 3’ leader and
the 5’ trailer, which are involved in regulating viral gene
transcription and genome replication [4].
At present, vaccination is the most effective method to
prevent rabies and the development of human rabies
vaccines follows a trend from brain passage to cell adap-
tation primarily because of safety considerations [5]. Ra-
bies vaccines have improved greatly since 1885 when
Louis Pasteur successfully vaccinated a boy who was. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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that had died of rabies as a vaccine for the first time.
Phenol was then employed to treat Pasteur’s vaccine, not
only for improved safety but also as a preservative to
prevent bacterial contamination [6,7]. To minimize the
adverse effects associated with nerve tissue vaccines
caused mainly by myelin in these preparations, avian
embryos and neonatal rodent brains were used to pre-
pare the human vaccine. However, although it was rela-
tively safer compared with nerve tissue vaccines,
significant poor antigenic responses and severe adverse
reactions were reported with embryo-derived rabies tis-
sue vaccines [8]. The advent of cell culture vaccines has
greatly improved the capacity for producing high quality
vaccines. The first tissue culture rabies vaccine was de-
rived from a virus grown in primary hamster kidney cells
in the 1960s, followed by the human diploid cell vaccine
(HDCV) in the mid-1970s [9,10]. An alternative to
HDCV was the use of purified chick embryo cells
(PCEC) [10] and vaccines produced from the Vero con-
tinuous cell lines [11]. During the past two decades,
there have been numerous attempts to develop alterna-
tives. The ability to clone the RABV G protein into bac-
terial plasmids and then express the protein in a range
of systems has led to a number of alternative approaches
with the potential for new vaccines against rabies
[12-17]. However, because of the cost and challenge of
gaining vaccine acceptance, cell culture vaccines will still
rank as the most commonly used human rabies vaccines
in the future [10].
Today, HDCV is the gold standard of rabies vaccines, but
its high cost limits its use around the world, especially in
developing countries. Alternatively, the PCECV, which is
prepared from a fixed RABV strain grown in primary cul-
tures of chicken fibroblast cultures, and it is much cheaper
and has a similar safety and potency compared to that of
HDVC. Therefore, the PCECV is a more advisable choice
for human inoculation. However, because CEC-adapted
RABV strains were not available, no PCECV has been used
for rabies prevention in China. In this study, we describe a
highly chick embryo cells (CECs) adapted RABV strain de-
rived from a China fixed vaccine CTN-1 strain called
CTNCEC25, and we investigate its biological properties
in vivo and in vitro. Given the high immunogenicity and
good propagation characteristics of the CTNCEC25 strain,
it has excellent potential for development into an inacti-
vated vaccine for human use. To the best of our knowledge,
this is the first report of a CTN-1 strain that has been
adapted to CECs and characterized systemically.
Results
Viral titers
To investigate the virus propagation properties during
their passage in cultured cells, each virus passage wasinvestigated. With serial passages in Vero cells, the titer
of the CTN-1 V strain initially increased rapidly, reach-
ing 109.0 FFU/ml at passage 15 (Figure 1). However, ini-
tially, when transferred to the chick embryo and CECs,
the viruses propagated poorly on the cells. The virus ti-
ters initially dropped sharply to a low of 104.5 FFU/ml in
the chick embryos and the first four CEC passages.
Thereafter, the settling increased gradually over the
course of the passages, and the viral titers increased
from passage 5 up to 107.3 FFU/ml at passage 31. The
virus titers then reached a plateau at 107.3-107.9 FFU/ml
between passages 32 and 57, indicating that the CTN-
1 V strain was adapted to grow in CECs, and this virus
strain was renamed the CTNCEC25 strain. However,
further passage in CECs induced a slight decrease in the
virus titer, and the virus only reached 106.2 FFU/ml at
passage 60 (Figure 1).
We also performed the MIT test to monitor the virulence
of different virus passages in adult mice. As shown in
Figure 1, the virulence of the virus dropped greatly to ap-
proximately 10-5.0 FFU/ml in the chick embryo passage and
at the early CEC passages from 10-9.0 FFU/ml of the paren-
tal CTN-1 V, which was correlated with that of the fluores-
cence focus inhibition test. However, although the virus
titers exhibited a stable increase during viral replication in
the CECs from passages 4 to 10, the viral virulence in adult
mice declined rapidly and was apathogenic at passage 20,
although the virus titers in the cultured cells were main-
tained at approximately 106.0 FFU/ml. These data indicated
that the virus completely lost its lethality in adult mice dur-
ing its adaptation to CEC.
Pathogenicity study
The MIT results shown above indicated that the CTN
CEC25 strain lost its lethality to adult mice. To further
determine the characteristics of the CTNCEC25 strain, a
pathogenicity comparison study between the CTNCEC25
(passage 36) and CTN-1 V strains in mice at different ages
was performed (Figure 2). The suckling mice inoculated i.c.
with CTN-1 V showed rabies signs at day 4 pi, and all of
the mice died at day 6 pi. As for the CTNCEC25 strain,
signs were observed at day 5 pi, and all of the mice died on
day 7 pi. Therefore, both the parental CTN-1 V strain and
the CTNCEC25 strain caused complete mortality in suck-
ling mice, although a one-day delay in the onset of disease
and death was noted in mice inoculated with CTNCEC25
compared with the CTN-1 V strain (Figure 2A).
Conversely, although the CTN-1 V strain caused no
deaths when injected intraperitoneally (i.p.) into adult mice,
it elicited 100% mice mortality by intracerebral (i.c.) inocu-
lation, and the mortality rates ranged from 60% to 10%
when injected intradermally (i.d.) or intramuscularly (i.m.),
depending on the mouse age, weight and administrative
route (Figure 2B-D). In contrast, the CTNCEC25 strain
Figure 1 Titers and LD50 change of the virus after passage in CECs. The CTN-1 V strain was propagated in Vero cells and then transferred to
CECs. The replication fitness of the virus in cultured cells or in adult mice were investigated using the fluorescence focus inhibition test (circle
solid line) and the MIT test (black triangle dotted line), respectively.
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and the administration route. In addition, all of the surviv-
ing mice inoculated with both viruses revealed no signs of
rabies such as weight reduction and hyperactivity (data not
shown), and the antibody titers from their serum ranged
from 4.10 IU/ml to 33.99 IU/ml. Therefore, the above re-
sults showed that the CTNCEC25 strain was apathogenic
to adult mice.
Immunogenicity
The immunological efficacy of the CTNCEC25 strain was
determined during passage in CECs. As shown in Figure 3,
the immunological efficacy of the CTNCEC25 strainFigure 2 Survival of mice inoculated with CTN-1 V and CTNCEC25. A.
strains. Mortality of 11–13 g (B), 18–20 g (C) or 28–30 g (D) adult mice inje
of ten two-day-old Kunming suckling mice or adult mice of different sizes
The clinical disease signs and death number were observed and scored da
mice was evaluated at the end of the experiment.increased with the adaptation process in CECs. The protec-
tion index grew > 100 after 15 passage levels, >1,000 after
30 passage levels, >100,000 after 33 passage levels, and it
reached the highest plateau of 128,825 at passage 45. The
high protection efficacy of the CTNCEC25 strain was
maintained from passage 33 to 55.
The results of the NIH test illustrated that vaccines
prepared using the CTNCEC25 viral strain (passage 36,
40, and 45) as a seed had a potency equal to 6.65 IU/ml,
6.45 IU/ml and 4.01 IU/ml, respectively, which were all
greater than the WHO-recommended standard of
2.5 IU/ml. The anti-rabies antibodies of mice immunized
with virus prepared from passage 36 is shown in Figure 4.Mortality of suckling mice injected i.c. with the CTN-1 V and CTNCEC25
cted i.c., i.p., i.d. and i.m. with the CTN-1 V or CTNCEC25 strain. A group
were inoculated with the CTNCEC25 and CTN-1 V strains, respectively.
ily for 21 days. The production of anti-rabies antibodies in surviving
Figure 3 The immunological efficacy of different viral passages
during adaptation to CECs. Adult mice were injected i.p. with
vaccine candidates or PBS as a negative control. At 14 days after the
first immunization, the adult mice were challenged by injecting i.c.
with serial ten-fold dilutions of standardized viruses of the CVS strain.
The numbers of mice dying of rabies between 4 and 14 days
post-challenge were recorded, and the protection index was
determined as the LD50 ratio of the experimental group to the LD50
of the control group.
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able antibody titres (mean titer: 14.7 IU/ml) as early as
3 days pi. The antibody titers rose quickly and reached a
plateau with an average titer of 43.41 IU/ml (ranging
from 18.94 to 113.78 IU/ml) at 14 days pi. After the
antibody titers plateaued, the antibodies decreased grad-
ually to a relatively low level but were constantly above
2.5 IU/ml.
These results indicated clearly that the CTNCEC25
strain could induce a strong protective immune response
in animals and that the CTNCEC25 strain has potential
for use as a viral seed for inactivated vaccine production.
Gene variation
The gene variation of the CTNCEC25 strain was tracked
during the adaptation process by sequencing the virus
structural protein genes N, P, M, G and L (Table 1). AFigure 4 The anti-rabies antibody levels of mice immunized
with virus prepared from the CTNCEC25 strain (passage 36). A
group of five adult mice was used for each day point, and the
potency of the prepared vaccine was determined according to the
NIH test. The highest, mean and lowest results are indicated.comparison of the genome sequences of the five structural
protein genes among strains at different passage levels re-
vealed that all five of the structural proteins except protein
P had a total of 15 nt changes. These mutations resulted in
eight amino acid substitutions (genome [nt] positions 2792,
3068, 3812, 4371, 4538, 4635, 4826, and 10212), with one in
protein L (aa 1602), two in protein M (aa 99 and 191) and
six in mature G protein (aa 147, 333, 389, 421 and 485), re-
spectively. All of these mutations occurred before 30 pas-
sages, and the viral genome maintained its stability from 30
to 55 passages in CECs (Table 1).
The CTNCEC25 strain’s genomic stability from 30 to
55 passages was further confirmed by whole genome se-
quencing at the 33, 45 and 55 passage levels. A compari-
son among these three passage strains revealed a 100%
shared identity at the whole genome nucleotide level
(unpublished data). The genomes of the CEC cell
culture-adapted virus contain 11,924 nt, with 17 changes
compared with the parental CTN-1 V and the nucleotide
sequences of these two viruses were 99.9% identical (un-
published data). In addition to the mutations in the
structural protein-coding regions mentioned above,
there was one deletion in the poly A tail of the P gene,
and there was one nucleotide substitution located at the
3’ untranslated region of the G gene. No changes were
observed in any other part of the CTNCEC25 viral
genome.
Discussion
In this study, we screened CEC-adapted RABV strain
CTNCEC25 from the CNT-1 V strain through serial pas-
sages in CECs. The virus titer change indicated that the
CTN-1 V strain gradually adapted to propagation in CECs
following the passages. During this adaptation process,
some of the viral characteristics changed. The most prom-
inent was that the passage of the virus in CECs reduces its
pathogenicity in adult mice. In adult mice, the CTNCEC25
strain was totally nonpathogenic at the highest tested dose
(as high as 107.9 FFU/ml) after passage level 20. Conversely,
the immunogenicity of the CTNCEC25 strain increased
during the mouse immunization test along with the passage
series in CECs, and the protection index reached up to
120,000 at passage 45, which was much higher than that of
the parental CTN-1 V strain and the standard for the
Pharmacopoeia of the People’s Republic of China (2010),
Volume III. The NIH potency of inactivated vaccines with-
out further concentration and based on the CTNCEC25
strain reached as high as 6.65 IU/ml, indicating that the im-
munogenicity of the CTNCEC25 strain is sufficient to per-
mit inactivated vaccine production.
The G protein is the most relevant component of the
RABV because of its multiple functions in the RABV repli-
cation cycle, such as its attachment to host cells, low pH-
dependent membrane fusion, viral virulence [18-20] and
Table 1 Sequence comparison of structural proteins among strains at different passage levels




















461 N-130 G/Arg A/- A/- A/- A/- A/- A/- A/- A/- A/-
2792 M-99 T/Leu G/Arg G/Arg G/Arg G/Arg G/Arg G/Arg G/Arg G/Arg
3068 M-191 C/Ser T/Leu T/Leu T/Leu T/Leu
3812 G-147 A/Lys G/Glu G/Glu G/Glu G/Glu
4371 G-333 G/Arg A/Gln A/Gln A/Gln A/Gln A/Gln A/Gln A/Gln
4538 G-389 G/Glu A/Lys A/Lys A/Lys A/Lys A/Lys A/Lys A/Lys A/Lys A/Lys
4635 G421 C/Pro A/Gln A/Gln A/Gln A/Gln
4636 A/Pro G/- G/- G/- G/- G/- G G G G
4826 G-485 T/Ser C/Pro C/Pro C/Pro C/Pro C/Pro C/Pro C/Pro C/Pro C/Pro
6289 L-294 A/Ser G/- G/- G/- G/- G/- G/-
7078 L-557 G/Leu A/- A/- A/- A/- A/-
7750 L-781 G/Glu A/- A/- A/- A/- A/- A/- A/- A/- A/-
9886 L-1493 G/Pro T/- T/- T/- T/-
10141 L-1578 A/Leu G/- G/- G/- G/- G/-
10212 L-1602 G/Arg A/Lys A/Lys A/Lys A/Lys
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[21]. Previous studies have demonstrated that the presence
of Lys/Arg-333 in mature G proteins in RABV is essential
for the lethality of the RABV strain in adult mice [18,22,23].
Our results indicated the Arg-333 in the CTN-1 V strain
was mutated to Gln-333 during serial passages in CECs
(Table 1). Accordingly, the pathogenicity of the CTNCEC25
strain also decreased greatly and totally lost viral virulence
in adult mice totally after passage level 20 (Figure 1). How-
ever, it was noted that the amino acid mutation at position
333 and the pathogenicity reduction were not synchronous
during CTN-1 V adaptation to CECs. The amino acid sub-
stitution of Arg-333 to Gln-333 was first detected at pas-
sage 6 in CECs, and the virulence of the CTNCEC25 strain
started to decrease at passage 11; the strain became totally
apathogenic to adult mice after passage 20. The delayed ef-
fect of mutating Arg-333 on the virulence of CTNCEC25
may be explained from two aspects. First, the Gln-333 sub-
stitution strain required natural screening through several
passages to be purified because the gene mutations of all
viral particles may not occur at the same time. Second, viral
reproduction was improving more and more in CECs fol-
lowing the serial passages, which could be verified by the
increasing virus titers from passage 6 to 10 (Figure 1).
Therefore, the impact of increasing the virus titer may off-
set some of the pathogenicity reduction effects of the virus
solution.
The mutation of Lys-147 to Glu-147, which is another
amino acid substitutions observed in the CTNCEC25
strain, may affect the function of the virus. Previous
studies have implicated the mutations of Lys-147 to
Gln-147 mutation in mature G proteins in RABV forreducing its pathogenicity after i.m. inoculation of the
virus into adult mice. Christophe Prehaud et al. 1988
also found that mutations in position aa 147 conferred
partial or total resistance to most MAbs that recognized
antigenic site II, suggesting this amino acid may be asso-
ciated with the viral immunogenicity [24-28]. In our
study, the CTNCEC25 strain had amino acid substitu-
tions at position aa 147 in passage 30. However, the dir-
ect pathogenicity reduction of CTNCEC25 at passage 30
for adult mice could not be detected because the virus
already had lost its pathogenicity for adult mice at pas-
sage 20, which could have occurred possibly because of
a Gln-333 substitution. However, the immunogenicity ef-
fect of the mutation was obvious. The protection index
increased to 4,266 at passage 30 from 600 at passage 25,
and it drastically increased up to more than 10,000 after
passage 33.
Likewise, amino acids at positions 34, 164, 182, 198,
200, 205, 210, 242, 255, 268, and 303 of mature G pro-
tein have been found to be associated with the patho-
genicity of RABV strains in adult mice [22,24,29,30].
However, none of these virulence-associated aa residues
were changed during the cell culture adaptation of the
CTN-1 V strain into the CTNCEC25 strain.
In addition to the two RABV pathogenicity-associated
amino acids mutations mentioned above, there were five
other amino acid substitutions in proteins G, L and M
in the CTNCEC25 strain. Following passage in the
CECs, these five amino acids were gradually changed.
Among these changes, the amino acid substitutions at
positions 389 and 485 of the G protein reverted to the
same ones found at the corresponding genome positions
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PV and SAG2, suggesting that these changes might be
involved in adapting to cell culture. Amino acid 1602 of
the L protein may not be conserved because the muta-
tion was found at this position in some other cell
culture-adapted strain and street isolates. Two other aa
site substitutions, namely aa 421 of the G protein and aa
99 of the M protein, were not found at the same genome
positions in street rabies virus isolates and other vaccine
strains, and their function requires further study.
In conclusion, we have successfully obtained a CEC-
adapted RABV CTNCEC25 strain from the CTN-1 V
strain by serial passage in CECs. The new adapted strain
CTNCEC25 lost virulence in adult mice but retains its
high immunogenicity and high propagation rate in cul-
tured cells, which make it an ideal candidate for inacti-
vated human vaccine production.
Materials and methods
Cell line and virus strain
Vero cells were obtained from the America Center for
Type Culture Collection (ATCC, CCL-81). BSR cells
were a gift from Professor Tangtsing of the Chinese
Centre for Disease Control and Prevention (CDC, P.R.
China). The RABV strain CTN-1 V, the CVS and an aG
adapted to the BSR cell line were provided by the Na-
tional Institute for Food and Drug Control, (NIFDC, P.
R. China). SPF eggs were supplied by Guangdong
DaHuaNong Animal Health Products Co., Ltd (Xinxin
County, Guangdong Province, P.R. China) and they were
incubated for 9 days to prepare the primary CECs.
Culture medium
Vero and BSR cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen, Glasgow, UK) sup-
plemented with fetal calf serum (FCS; 3–10%; Gibco
Invitrogen cell culture, Glasgow, UK). Primary CECs
were maintained in Medium 199 (M199, Invitrogen,
Glasgow, UK) supplemented with 10% FCS and 1% hu-
man albumin (Shenzhen Weiguang Biological Products
Co., Ltd, Shenzhen, P.R. China). Tryptose phosphate was
supplied by Invitrogen (Glasgow, UK).
Virus titration
The virus titer was determined using a modified rapid
fluorescence focus inhibition test as previously described
[31] and expressed in fluorescent focus units (FFU)/ml.
Briefly, a monolayer of BSR cells in 96-well plates was
incubated with serial three-fold virus dilutions. At 24 h
post-infection (pi), the cells were fixed with 80% ice-cold
acetone and stained with a FITC-labeled N-protein-
specific monoclonal antibody (Millipore). The plates
were examined by fluorescence microscopy (Olympus
Corp., Tokyo, Japan), and the number of fluorescent focipresented in the wells was recorded. Endpoints were de-
fined as the highest dilutions with fluorescent foci less
than 30, and virus titers were calculated by the following
formula: virus titer (FFU/ml) = (the mean foci number in
the endpoint wells × 5 + the mean foci number in the
wells with lower dilutions next to the endpoint well) ÷
2 × the dilution factor of the lower dilutions × 20.
Virus propagation and passage in primary CECs
The CEC-adapted CTN-1 V strain CTNCEC25 was pre-
pared as follows. Firstly, the CTN-1 V strain was propa-
gated in Vero cells for 10 passages. For each passage, the
virus was cultivated on monolayer of Vero cells in
DMEM supplemented with newborn calf serum at 35 -
37°C in a 5% CO2 humidified incubator at a 10
−2- 10−3
dilution for 4–6 days, and the virus-containing super-
natant was then transferred to the second passage of
Vero cells in the same dilution. Then, the virus-
containing supernatant was transferred to 9-11-day-old
chick embryos at a dilution of 10−1 - 10−2, and were in-
cubated at 35 – 37°C for another 7 days. Finally, the pri-
mary CECs were infected with the virus produced in
chick embryos at a cell concentration of 1 × 106 cells/ml
with a multiplicity of infection (MOI) of approximately
0.001 - 0.05 FFU/cell. Virus propagation was performed
at 33-35°C in 25-cm2 Kolle flasks containing 5 ml of
M199 supplemented with human serum albumin and
newborn calf serum for 4–5 days of incubation. This
step was continued and optimized until an acceptable
virus titer was reached (≥107 FFU/ml). The resulting
CEC-adapted CTN-1 V strain was named CTNCEC25
(GenBank accession no. KJ466147).
Mouse Inoculation Test (MIT)
Viral virulence in adult mice was measured in 4-week-
old Kunming mice. Groups of five adult mice were intra-
cerebrally (i.c.) inoculated with 0.03 ml of serial 10-fold
dilutions of each virus. Clinical disease signs and death
numbers were observed and scored daily for 14 days.
Any death occurring during the first three days was dis-
carded as a nonspecific death. The median lethal dose
(LD50) of each virus was calculated using the Reed and
Muench method [32].
Pathogenicity assay
A pathogenicity study of the viruses was performed
using an in vivo infection model as previously described
[33]. A group of ten two-day-old Kunming suckling mice
was inoculated i.c. with 0.03 ml, or ten adult mice of dif-
ferent sizes were inoculated i.c. with 0.03 ml, intramus-
cularly (i.m.) with 0.1 ml, intraperitoneally (i.p.) with
0.5 ml or intradermally (i.d.) with 0.1 ml of the
CTNCEC25 (107.91 FFU/ml) and CTN-1 V (107.98 FFU/
ml) strains, respectively. Clinical disease signs and death
Table 2 Primers used to amplify the CTNCEC25 structural
protein gene sequence
Primer Sequence (5′→ 3′) Target gene
N-F ACGCTTAACAACCAAATCAAAG N
N-R TTGACGAAGATCTTGCTCAT
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death occurring during the first three days was recorded,
any dead mouse was then discarded. The production of
anti-rabies antibodies in surviving mice was evaluated at








L2-F TGGAAATTCAGGTTATGAAGTCPreparation of the experimental vaccine
Test vaccines were prepared from seed material adapted
to primary CECs in accordance with the virus produc-
tion process in primary CECs as specified above. The
harvested viruses were first clarified by filtration through
a 0.65-μm filter and then inactivated using β-
propiolactone. The vaccine was then evaluated using an
NIH test and a mouse protection test by comparing the







Vaccine candidates were injected i.p. into adult mice (12–
14 g, 0.5 ml; 1 dilution per group) on days 0 and 7. Mice
injected with PBS instead of vaccines were used as negative
controls. Fourteen days after the first immunization, both
the experimental and control groups were challenged with
i.c. injections in serial ten-fold dilutions of standardized
virus (CVS strain, 0.03 ml, 10 mice per dose). The numbers
of mice dying of rabies between 4 and 14 days post-
challenge were recorded, and the protection index was de-
termined as the ratio of the LD50 of the sample group to
that of the control group. Serum samples were collected
from surviving animals for an indirect fluorescent antibody
(IFA) test, as previously described [34], for the anti-rabies
antibodies at the end of the experimental period (days 7,
14, 21, 28 and 42).Vaccine potency test
Three passage (passage 36, 40 and 45) viruses were selected
to produce vaccines without concentration. The potency of
the prepared vaccine was determined according to the NIH
test [35]. Groups of 16 4–6 week-old Kunming mice were
given two 0.5 ml doses of different vaccine dilutions i.p. on
days 0 and 7. The immunization was followed by an i.c.
dose of the challenge virus standard (CVS) strain (0.03 ml,
containing 32 LD50) dose 14 days after the first vaccine in-
oculation. A national reference calibrated to the inter-
national reference vaccine and a titration of the challenge
virus was included in each test series. The median effective
dose (ED50) value of the vaccine under examination was
calculated and compared with the ED50 of the national ref-
erence preparation, and the relative potency of the vaccine
was calculated and expressed in International Units (IU/
ml). In addition, the anti-rabies antibodies of mice immu-
nized with vaccine prepared from passage 36 were detected
using IFA tests at days 3, 7, 10, 14, 21, 28 and 42 pi.DNA sequencing
Genomic RNA was extracted from the viruses at differ-
ent passage levels with a QIAamp Ultrasens Virus Kit
(QIAGEN) according to the manufacturer’s instructions.
Full-length cDNA was synthesized using First Strand
cDNA Synthesis Kit-Rever Tra Ace-α reverse primer
(Toyobo Life Science, Shanghai, China). According to
the CTN-1 genome sequence (GenBank accession no.
FJ959397), 9 pairs of primers (Table 2) were designed to
amplify genes encoding the structural proteins N, P, M,
G and L of the virus of some passages from their full-
length cDNA sequences. The PCR products were then
subjected to nucleotide sequencing by BGI-Shenzhen,
Shenzhen, P. R. China. The full-length cDNA of selected
passages was directly subjected to nucleotide sequencing
by BGI-Beijing, Beijing, China and Invitrogen Life Tech-
nologies Corporation, Shanghai, P. R. China.
Animal experiment
Kunming mice were supplied by the Medical Experi-
mental Animal Center of Guangdong Province (Guang-
dong, China). The care and use of laboratory animals
was approved by the Animal Care and Use Committee
of Weiguang Biological Products Co., Ltd. All animals
were treated humanely and euthanized by cervical dis-
location (mice) at the end of the experimental period.
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